Journal
CANCER INVESTIGATION
Volume 40, Issue 7, Pages 590-603Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357907.2022.2069254
Keywords
Osimertinib; almonertinib; furmonertinib
Categories
Ask authors/readers for more resources
This article reviews the research advances of three third-generation EGFR-TKIs, namely osimertinib, almonertinib, and furmonertinib, in terms of pharmacokinetics, pharmacodynamics, treatment-related adverse events, and other aspects. Individualized optimization of third-generation EGFR-TKIs options may provide maximum benefits to NSCLC patients with EGFR T790M mutation.
Osimertinib, almonertinib and furmonertinib are third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. This article reviews research advances in pharmacokinetics, pharmacodynamics, treatment-related adverse events, and other aspects related to the three EGFR-TKIs were systematically reviewed in order to provide references for clinical drug selection. There are differences in dosing schedule and incidence of adverse events among three drugs. Optimization of third-generation EGFR-TKIs options for individuals may produce the maximal benefits to NSCLC patients with EGFR T790M mutation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available